Search Results
Your search for The ASCO Post matches 17389 pages
Showing 11651 - 11700
Joseph A. Sparano, MD, on Early-Stage Breast Cancer: Findings on the Tumor Microenvironment
Joseph A. Sparano, MD, of the Montefiore Medical Center, discusses the tumor microenvironment of metastasis score and its association with early distant recurrence in HR-positive, HER2-negative early-stage breast cancer (Abstract S4-04). To view a short film on capturing imaging inside breast...
Hyo Sook Han, MD, on Metastatic Breast Cancer: Trial Results on Veliparib, Carboplatin, and Paclitaxel
Hyo Sook Han, MD, of Moffitt Cancer Center, discusses phase II study findings on the efficacy and tolerability of veliparib in combination with carboplatin and paclitaxel vs placebo in patients with BRCA1 or BRCA2 mutations and metastatic breast cancer (Abstract S2-05).
Anne Hudson Blaes, MD, on Aromatase Inhibitors and Cardiovascular Disease
Anne Hudson Blaes, MD, of the University of Minnesota, discusses the association between aromatase inhibitors, endothelial function, and early heart disease (Abstract S5-07).
Jame Abraham, MD, on Hair Loss: SCALP Trial Results
Jame Abraham, MD, of the Cleveland Clinic, discusses findings of the Scalp Cooling Alopecia Prevention trial for patients with early-stage breast cancer (Abstract S5-02).
Jame Abraham, MD, on ER-Positive Breast Cancer: Expert Perspective on Initial Results of NRG Oncology/NSABP B-42
Jame Abraham, MD, of the Cleveland Clinic, gives his perspective on study results of extended adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer who have completed previous adjuvant endocrine treatment (Abstract S1-05).
Pioneer in Cancer Immunology, Richmond T. Prehn, MD, Dies
Until 1957, the prevailing thought was that since cancers develop in normal patients, they are not recognized as foreign by the immune system. That changed when Richmond T. Prehn, MD, and his laboratory assistant, Joan Main, showed that tumors induced by chemical carcinogens in mice could...
Investigational Immunotherapy for Advanced Melanoma
The investigational immunotherapeutic IMC-20D7S was found to be well tolerated and somewhat active in patients with advanced melanoma, including one complete response, according to the results of a phase I/Ib trial reported by Danny N. Khalil, MD, PhD, and colleagues in Clinical Cancer Research....
Characteristics of HPV-Driven Nonoropharyngeal Squamous Cell Carcinomas of the Head and Neck
In a study reported in the Journal of Clinical Oncology, Chakravarthy et al found that human papillomavirus (HPV)-driven tumors accounted for 4.1% of nonoropharyngeal squamous cell carcinomas of the head and neck. HPV-positive tumors were associated with poorer survival and reduced...
Intensity-Modulated vs Three-Dimensional Conformal External-Beam Radiation Therapy in Locally Advanced Non–Small Cell Lung Cancer
In a secondary analysis from the NRG Oncology RTOG 0617 trial reported in the Journal of Clinical Oncology, Stephen G. Chun, MD, of the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, and colleagues found that use of intensity-modulated vs three-dimensional...
George A. Komatsoulis, PhD, Joins CancerLinQ LLC as Chief of Bio-Informatics
CancerLinQ LLC has announced that George A. Komatsoulis, PhD, will be its first Chief of Bio-Informatics. This marks another step toward the organization’s goal of making the CancerLinQ® platform the premier system for unlocking patient data from millions of electronic health records, breaking...
Expect Questions About Cardiovascular Risk Factors Among Cancer Survivors
Reports of rare, but in some cases fatal, cardiac complications when the checkpoint inhibitors ipilimumab (Yervoy) and nivolumab (Opdivo) are used in combination should be taken seriously but should not scare patients away from potentially life-saving drugs, according to Javid J. Moslehi, MD. Dr....
Cardiac Complications in Patients Receiving Combination Checkpoint Inhibitors Are Rare but Can Be Fatal
Cardiovascular toxicities associated with cancer treatments are not new. What is new, and what has prompted recent articles in The New England Journal of Medicine,1,2 is the explosion of cancer therapies, which has dramatically changed the natural course of many cancers but can lead to cardiac,...
Ruth O’Regan, MD, and Ann H. Partridge, MD, on The NRG Oncology/NSABP B-42, IDEAL, and DATA Studies
Ruth O’Regan, MD, of the University of Wisconsin, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss study findings from a session Dr. O’Regan moderated on three major trials addressing anastrozole after tamoxifen in HR-positive early breast cancer, letrozole in HR-positive...
SABCS 2016: Women Experiencing Menopausal Symptoms Less Likely to Adhere to Medication in IBIS-1 Trial
Among women enrolled in the International Breast Cancer Intervention Study I (IBIS-I), those who had certain symptoms of menopause—nausea/vomiting and headaches—were significantly less likely to be adherent to the assigned medication 4.5 years after starting the treatment, according to...
NIH Statement on the Death of Former Congressman Melvin R. Laird
“I am greatly saddened by the death of former Congressman Melvin R. Laird, who, over the course of his distinguished career in public service, played a key role in advancing biomedical research and the mission of the National Institutes of Health (NIH). Our thoughts are with his family and the...
SABCS 2016: Neoadjuvant Abemaciclib Treatment May Benefit Patients With Early-Stage Hormone Receptor–Positive, HER2-Negative Breast Cancer
Presurgical treatment with the investigational therapeutic abemaciclib, either alone or in combination with the aromatase inhibitor anastrozole, reduced levels of Ki67, a marker of cell proliferation, in hormone receptor–positive, HER2-negative breast cancer cells, compared with anastrozole...
SABCS 2016: BELLE-3 Trial of Buparlisib Plus Endocrine Therapy Meets Primary Endpoint of Progression-Free Survival in Breast Cancer Patients
The investigational PI3K inhibitor buparlisib, in combination with endocrine therapy, improved outcomes for patients with hormone receptor–positive advanced breast cancer that had progressed after treatment with everolimus (Afinitor) plus exemestane, according to data from the phase III...
SABCS 2016: Adding Veliparib to Chemotherapy Improved Response Rates Among Patients With BRCA-Mutant Breast Cancer
Adding the investigational poly ADP ribose polymerase (PARP) inhibitor veliparib to carboplatin and paclitaxel chemotherapy improved the overall response rate without increasing adverse events among patients who had locally recurrent or metastatic breast cancer with BRCA1 or BRCA2 mutations,...
Samuel Smith, PhD, on Tamoxifen Adherence: Results of the IBIS-1 Study
Samuel Smith, PhD, of Queen Mary University of London, discusses study findings on menopausal symptoms as predictors of long‐term adherence in an International breast cancer intervention study (Abstract S5-03).
Harold J. Burstein, MD, PhD, on Adjuvant Endocrine Therapy: Expert Perspective
Harold J. Burstein, MD, PhD, from Dana-Farber Cancer Institute, gives an update on the duration of adjuvant endocrine therapy and offers his expert views on putting the research data into clinical practice.
2017 Oncology Meetings
JANUARY 2017 2017 Oncologic Emergency Medicine ConferenceJanuary 12-13 • Houston, Texas For more information: www.mdanderson.org/education-training/professional-education/cme-conference-management/conferences/oncologic-emergency-medicine-conference.html Advances in Medical and Surgical Management...
Sara A. Hurvitz, MD, on HR-Positive, HER2-Negative Breast Cancer: Results of the neoMONARCH Trial
Sara A. Hurvitz, MD, of the UCLA Jonsson Comprehensive Cancer Center, discusses findings on the biological effects of abemaciclib in a neoadjuvant study for postmenopausal patients (Abstract S4-06).
Aleix Prat, MD, PhD, on HER2-Positive Breast Cancer: First Results of the PAMELA Trial
Aleix Prat, MD, PhD, of the University of Barcelona, discusses study findings on intrinsic subtype as a predictor of pathologic complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer (Abstract S3-03).
Advocacy Group to Fund $1.6 Million in Grants for 8 Early Detection Ovarian Cancer Research Projects
Tina’s Wish, a nonprofit organization dedicated exclusively to funding scientific research for the early detection of ovarian cancer, recently announced its eight 2017–2018 individual grant recipients after soliciting proposals nationally for the first time. Researchers from Dana-Farber Cancer...
Ruth O’Regan, MD, and Ann H. Partridge, MD, on HER2+ Breast Cancer: Results From the CLEOPATRA Trial
Ruth O’Regan, MD, of the University of Wisconsin, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss study findings on the prognostic associations of TILs in metastatic HER2-positive breast cancer (Abstract S1-04).
Team-Based Care in Oncology: National Cancer Institute and ASCO Launch Unique Project
In its November 2016 issue, the Journal of Oncology Practice (JOP) has published a special series that represents the results of a unique project launched in 2014 by ASCO and the National Cancer Institute (NCI) to heighten awareness of ways to enhance team-based care in oncology. Concerns about...
SABCS 2016: Radiation Therapy May Increase Complications in Breast Cancer Patients Receiving Implants
Radiotherapy increased complications and impaired patient-reported satisfaction with reconstructed breasts in breast cancer patients who received implant reconstruction, but not in those who received autologous reconstruction, according to data from a large, prospective, multicenter cohort study...
SABCS 2016: Adding Ibandronate to Hormone Therapy Did Not Improve Outcomes for Postmenopausal Breast Cancer Patients
Postmenopausal women with hormone receptor–positive early-stage breast cancer who received the bisphosphonate ibandronate (Boniva) in addition to adjuvant hormone therapy did not have improved disease-free survival outcomes, according to data from the phase III clinical trial TEAM IIB...
SABCS 2016: No Added Benefit With Aromatase Inhibitor as Part of Presurgical Therapy for Hormone Receptor–Positive, HER2-Positive Breast Cancer
Adding an aromatase inhibitor to presurgical treatment with docetaxel, carboplatin, trastuzumab (Herceptin), and pertuzumab (Perjeta) did not significantly increase or decrease the percentage of patients with hormone receptor–positive, HER2-positive breast cancer who had a pathologic...
SABCS 2016: Axillary Lymph Node Dissection Might Be Avoidable for Certain Early-Stage Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
A sentinel lymph node biopsy during surgery that showed no signs of cancer was associated with a low risk for breast cancer recurrence in the axillary lymph nodes for patients with large, operable breast tumors and no clinical signs of the cancer in the axillary lymph nodes prior to neoadjuvant...
Matt Ewend, MD, FACS, Named President of the University of North Carolina Physicians
Matt Ewend, MD, FACS, has been named President of the University of North Carolina (UNC) Physicians. In this role, Dr. Ewend will oversee the physician clinical enterprise of UNC Health Care, which includes more than 2,400 physicians and 600 advanced practice providers in 450 practices spanning...
Seven MD Anderson Faculty Elected Fellows of the American Association for the Advancement of Science
In recognition of wide-ranging contributions to the fields of cancer prevention; patient care; and basic, translational, and clinical research, seven faculty members from The University of Texas MD Anderson Cancer Center have been named Fellows of the American Association for the Advancement of...
Palliative Care Improves Quality of Life, Relieves Symptoms
People living with serious illness who receive palliative care have better quality of life and fewer symptoms than those who don’t receive palliative care, according to a new study by researchers at the University of Pittsburgh School of Medicine. Published by Dio Kavalieratos, PhD, Assistant...
Using Art to Humanize Medicine
Among the most widely attended sessions at the 2016 Palliative Care in Oncology Symposium in September was the keynote lecture, “Wit, Hex, Vin, Life, Death: Using Wit as a Teaching Tool,” given by Margaret Edson, author of the Pulitzer Prize–winning play Wit. Wit tells the story of an accomplished ...
Approval of Dinutuximab for High-Risk Neuroblastoma: Lessons Learned in Expediting the Development of Pediatric Cancer Drugs
On March 10, 2015, the U.S. Food and Drug Administration (FDA) granted regular approval to dinutuximab (formerly known as chimeric 14.18 antibody; Unituxin) for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid...
Stephen R.D. Johnston, MBBS, PhD, and Ann H. Partridge, MD, on Breast Cancer: Managing Metastatic ER+ Disease
Stephen R.D. Johnston, MBBS, PhD, of The Royal Marsden NHS Foundation Trust, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss the role of endocrine therapy and optimal sequencing, recent progress in first-line treatment, and resistance pathways and second-line treatment...
Jennifer K. Litton, MD, and Ann H. Partridge, MD, on Breast Cancer in Young Women
Jennifer K. Litton, MD, of MD Anderson Cancer Center, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss a range of issues for young women with breast cancer, including epidemiologic and biologic differences in younger patients, fertility issues, and pregnancy-associated breast...
Dawn Hershman, MD, on Breast Cancer Survivorship: Poster Discussion
Dawn Hershman, MD, of the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, reviews findings on survivorship care plans, interventions to reduce chemotherapy-induced peripheral neuropathy, and the cardiac effects of aromatase inhibitors (Poster Discussion 4).
Jennifer A. Ligibel, MD, on Gene Expression: Study Findings
Jennifer A. Ligibel, MD, of Harvard Medical School, discusses the impact of preoperative exercise on breast cancer gene expression (Abstract S5-05).
Rowan T. Chlebowski, MD, PhD, on Diet and Breast Cancer: Trial Results
Rowan T. Chlebowski, MD, PhD, of the David Geffen School of Medicine at UCLA, discusses findings from the Women’s Health Initiative Dietary Modification study on low-fat diet and breast cancer overall survival (Abstract S5-04).
Integrating AYA Oncology Care Into the Worlds of Pediatric and Adult Oncology Care to Improve Cancer Outcomes
GUEST EDITORAdolescent and Young Adult Oncology explores the unique physical, psychosocial, social, emotional, sexual, and financial challenges adolescents and young adults with cancer face. The column is guest edited by Brandon M. Hayes-Lattin, MD, FACP, Associate Professor of Medicine and...
Faculty Development in Oncology: Advancing the Field by Optimizing Opportunities for Educators to Learn and Grow
In 2015, Janet Riddle, MD, and her colleagues published an article1 outlining 12 key themes for delineating how fellowship programs in medical education should be developed (See “12 Tips for Developing Successful Fellowship Programs for Medical Educators,” below.) The ASCO Post talked with Dr....
Steven K. Libutti, MD, FACS, Named Director of Rutgers Cancer Institute of New Jersey
Steven K. Libutti, MD, FACS, has been named the new Director of Rutgers Cancer Institute of New Jersey and will serve as Vice Chancellor for Cancer Programs for Rutgers Biomedical and Health Sciences at Rutgers University. When he takes on his new roles in early 2017, Dr. Libutti will be the third ...
Peer-Reviewed Indian Journal of Surgical Oncology Meets Challenges, Succeeds in Developing Country
Launching a new cancer journal is a risky and arduous endeavor, especially for a specialty publication in resource-challenged countries in the developing world. To succeed, a specialty journal must publish articles from established clinical researchers that quickly garner funding and captivate its...
Maura Gillison, MD, PhD, Elected to National Academy of Medicine
Maura Gillison, MD, PhD, a physician-researcher who has made significant contributions to the fields of cancer biology, therapy, and epidemiology, was elected a member of the National Academy of Medicine during the Academy’s annual meeting. Dr. Gillison is the Jeg Coughlin Chair in Cancer...
The Leukemia & Lymphoma Society Invests $40.3 Million in New Research to Find Cures for Hematologic Malignancies
The Leukemia & Lymphoma Society (LLS) has announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute; Weill Cornell Medicine; Memorial...
Statement From the American Association for Cancer Research on the House Passage of the 21st Century Cures Act
From Nancy E. Davidson, MD, President of the AACR and Executive Director of the Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, and Margaret Foti, PhD, MD (hc), Chief Executive Officer of the AACR On behalf of the American Association for Cancer Research (AACR),...
Roy S. Herbst, MD, PhD, Receives 2016 Paul A. Bunn Jr. Scientific Award
Roy S. Herbst, MD, PhD, of Yale University, New Haven, Connecticut, was recognized by the International Association for the Study of Lung Cancer (IASLC) with a distinguished award at the 17th World Conference on Lung Cancer in Vienna, Austria. Dr. Herbst accepted the Paul A. Bunn Jr. Scientific...
AAAS Names Winship’s Dong Moon Shin, MD, as a 2016 Fellow
Dong Moon Shin, MD, the Frances Kelly Blomeyer Distinguished Endowed Chair in Cancer Research at Winship Cancer Institute of Emory University, has been named a Fellow of the American Association for the Advancement of Science (AAAS). Dr. Shin is Professor of Hematology and Medical Oncology,...
Mylin A. Torres, MD, to Hold Glenn Family Chair in Breast Cancer Research at Winship Cancer Institute
Mylin A. Torres, MD, Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University (Winship), was selected to hold the Louisa and Rand Glenn Family Chair in Breast Cancer Research. The endowed position was created by the Wilbur and Hilda Glenn Family Foundation to...
